These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 29177842

  • 21. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
    Pennington B, Ren S, Barton S, Bacelar M, Edwards SJ.
    Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
    [Abstract] [Full Text] [Related]

  • 22. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
    Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I.
    Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
    [Abstract] [Full Text] [Related]

  • 23. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE, Witlox W, Wolff R, Chalker A, Hiligsmann M, Wijnen B, Ahmadu C, Ryder S, Armstrong N, Duffy S, Syndikus I, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
    [Abstract] [Full Text] [Related]

  • 24. Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Claxton L, O'Connor J, Woolacott N, Wright K, Hodgson R.
    Pharmacoeconomics; 2019 May; 37(5):645-654. PubMed ID: 30298279
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE, Armstrong N, Ramaekers BLT, Pouwels X, Lang S, Petersohn S, Riemsma R, Worthy G, Stirk L, Ross J, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2019 May; 37(5):655-667. PubMed ID: 30293207
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Witlox W, Grimm S, Howick J, Armstrong N, Ahmadu C, McDermott K, Otten T, Noake C, Wolff R, Joore M.
    Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
    [Abstract] [Full Text] [Related]

  • 31. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
    Fleeman N, Bagust A, Beale S, Boland A, Dickson R, Dwan K, Richardson M, Dundar Y, Davis H, Banks L.
    Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S, Bermejo I, Simpson E, Wong R, Scott DL, Young A, Stevenson M.
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [Abstract] [Full Text] [Related]

  • 34. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D, Armoiry X, Auguste P, Court R, Mantopoulos T, Patterson J, De Santis M, Cresswell J, Mistry H.
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A, Underhill S, Fougeray R, Hatswell AJ.
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Walton M, Sharif S, Simmonds M, Claxton L, Hodgson R.
    Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
    [Abstract] [Full Text] [Related]

  • 38. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N, Bagust A, Boland A, Beale S, Richardson M, Krishan A, Stainthorpe A, Abdulla A, Kotas E, Banks L, Payne M.
    Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
    [Abstract] [Full Text] [Related]

  • 39. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S.
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [Abstract] [Full Text] [Related]

  • 40. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Rose M, Shepherd J, Harris P, Pickett K, Lord J.
    Pharmacoeconomics; 2018 Nov; 36(11):1299-1308. PubMed ID: 29691773
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.